STAT+: Biotech execs, academic expert lament impact of FDA turnover on rare disease drug development

Biotech executives and an academic expert discuss the impact of FDA turnover on rare disease drug development, citing anxiety and uncertainty. Mahzi Therapeutics CEO Yael Weiss shares her experience with investor concerns. The debate focuses on the flexibility the FDA should allow in clinical trial design.